MHRA sets out a 2030 blueprint for regulation built around AI, data and faster access
The MHRA has published a 2030 strategy that redraws the regulator’s priorities around patient access, digital health, real-world evidence and tighter enforcement against illegal medicines. The plan is framed for an era in which AI, advanced diagnostics, cell and gene therapies, genomics and personalised medicines are no longer distant concepts but part of routine development pipelines that now press against older regulatory structures.
One sentence captures the shift plainly: the agency wants to move faster without loosening standards.
The strategy positions the MHRA as a regulator that should be more data-connected, more internationally aligned and more responsive to the pace of biomedical innovation across the UK. It also places patients closer to the centre of decision-making, with a stated aim of improving access to safe and effective treatments while maintaining public protection. For companies developing medicines and devices, the message is equally direct: the route to market should be clearer, quicker and more predictable, but only if evidence generation keeps pace with the complexity of the products being assessed.
Real-world evidence and surveillance move to the foreground
A major theme running through the strategy is the use of real-world data from hospitals, genomics and routine care. The MHRA wants to strengthen its ability to detect safety issues earlier by using specialised expertise and AI to analyse large datasets, while also working with the Health Data Research Service on real-time surveillance. In regulatory terms, this matters because traditional pre-market trials rarely capture every safety question that emerges once a medicine, device or digital tool is used at scale in heterogeneous populations.
The plan also reaches into device oversight. Better collection and use of medical device data, along with more precise traceability throughout a device’s lifecycle, would make recalls, field safety notices and post-market monitoring easier to execute. Faster and simpler Yellow Card reporting is meant to lower the barrier for patients and healthcare professionals who want to report adverse events involving medicines or devices. In practical terms, that could improve signal detection when a rare harm is emerging and every day of delay carries clinical consequences.
Faster review pathways are built into the operational plan
The strategy does not limit itself to broad ambition. It contains operational commitments designed to change how quickly the MHRA moves on applications. One proposal would create a higher-value service option that cuts scientific advice from 90 days to 45 days for medicine and medical product developers. Another would halve the initial assessment target for qualifying Phase 1 clinical trials to 14 days. Faster decisions on generic and biosimilar products are also promised, with the goal of accelerating patient access and bringing NHS savings forward sooner.
Those timeframes matter because they affect where innovation stalls. Early regulatory uncertainty can delay trial initiation, slow investment and push development activity elsewhere. Shorter timelines, if delivered without lower evidentiary standards, may help smaller sponsors and academic groups as much as large manufacturers, especially when a first-in-human study depends on rapid feedback from regulators before a protocol can proceed.
Patient-centred regulation is being pushed beyond rhetoric
The strategy also includes a broader patient-centred agenda. The MHRA wants more diversity in clinical studies and has committed to a Women’s Health Plan this year, with the stated goal of improving outcomes for women and narrowing health gaps between ethnic groups. It also plans to strengthen patient contributions to regulatory decisions and publish a refreshed Patient and Public Involvement and Engagement Plan.
This is not a cosmetic addition. Underrepresentation in studies still leaves regulators and clinicians with incomplete evidence on efficacy, dosing, tolerability and risk in populations that often bear a disproportionate burden of disease. Better inclusion changes the quality of the evidence base itself, and that can influence everything from label language to post-marketing monitoring and shared decision-making in clinic.
Illegal medicines and online harm remain part of the remit
The strategy gives equal weight to enforcement. The MHRA intends to increase criminal enforcement capacity to investigate, disrupt and prosecute illegal medicines and medical device activity, while also working with social media platforms and online marketplaces to limit misinformation and stop harmful products reaching the public. That part of the plan reflects a modern regulatory reality: unsafe products are not only sold through traditional channels, but also spread through digital ecosystems where speed, reach and anonymity make enforcement harder.
The public health stakes are immediate. When counterfeit or unlicensed products circulate online, patients can be exposed to ineffective treatment, toxic ingredients or devices with no credible performance data. A regulator that can move quickly against those supply chains is not just preserving market integrity; it is preventing avoidable harm before patients encounter it.
AI oversight and human-relevant science define the innovation agenda
The plan also sketches a future in which regulatory science adapts to technologies that do not fit old templates. The MHRA wants to develop an AI-enabled Clinical Trial Protocol Checker to give sponsors regulatory certainty and support higher-quality trial applications. It also plans to publish an AI Medicines Development Action Plan in 2027, establish an MHRA Centre for AI and Digital Health, and create a modern regulatory framework for AI as a medical device.
Alongside that digital agenda sits a shift away from animal models toward human-relevant new approach methodologies, including organoids. The aim is to make preclinical testing more biologically relevant while improving translation into human disease. For rare disease therapies, the agency wants a more flexible and risk-proportionate framework, paired with stronger links between the UK’s genomics capability and the NHS. These are not isolated initiatives; together they point toward a system that treats molecular data, computational tools and human tissue models as central evidence sources rather than peripheral ones.
International reliance is being turned into a strategic lever
The MHRA also plans to deepen cooperation with trusted regulators, including expanded reliance and recognition routes with the US FDA and continued recognition of CE-marked devices. It aims to use Regulatory Innovation Corridors to reduce duplication and accelerate movement toward clinical studies, while chairing the Access Consortium to support faster access to medicines across Australia, Canada, Singapore, Switzerland and the UK.
International collaboration has become more than administrative convenience. For globally developed medicines and devices, overlapping reviews can slow access without improving safety if regulators are asking similar questions using similar standards. Shared scientific work, when it is genuinely interoperable, can cut delay and free capacity for areas where local expertise is most needed.
The strategy leaves one practical question hanging over all of its ambitions: whether the agency can deliver faster decisions, deeper surveillance and more sophisticated AI oversight at the same time, with the staffing, data infrastructure and enforcement muscle those commitments require. The answer will shape whether the 2030 plan becomes a real regulatory reset or remains a map of intentions.